Advert - Camurus – AUTH/3404/10/20

Promotion of Buvidal

For failing to include obligatory information and certify promotional materials for Buvidal (buprenorphine) and for failing to fairly reflect Camurus’ role and responsibility in relation to two promotional webinars which were, in addition, not restricted to health professionals and other relevant decision makers and were thus considered to be promoting Buvidal to the public, Camurus was ruled in breach of the following clauses of the Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the pharmaceutical industry
Clause 4.1 - Failing to include prescribing information
Clause 4.3 - Failing to include the non-proprietary name immediately adjacent to the most prominent display of the brand name
Clause 4.9 - Failing to include information about how to report adverse events
Clause 9.1 - Failing to maintain high standards
Clause 9.10 - Failing to clearly indicate its role and responsibility in relation to two promotional webinars
Clause 12.1 - Disguising promotional material
Clause 14.1 - Failing to certify promotional material
Clause 26.1 - Promoting a prescription only medicine to the public
Clause 26.2 - Encouraging members of the public to ask for a specific prescription only medicine
Clause 28.1 - Failing to restrict access to promotional material to health professionals and other relevant decision makers

Advert Aug 2021